Currently there is an increase in the use of bioprosthesis worldwide (\> 70% according to national data of the Spanish Society of Thoracic and Cardiovascular Surgery). There is conflicting evidence regarding the long-term survival of patients aged 50-65 years with mechanical (M) or biological (B) aortic prostheses. General consensus of greater complications associated with the use of long-life anticoagulation in M and of reoperation in B. Similar survival with lower MACCE complications in bioprosthesis could reconsider their choice in patients aged 50-65 years, specially in the current TAVI era. The investigators are going to perform a multicentric retrospective observational study (Registry) about 15 year-outcomes Following Bioprosthetic vs Mechanical Isolated Aortic Valve Replacement for Aortic Stenosis in Patients Aged 50 to 65 Years in 30 Cardiovascular Surgery Centers in Spain
Objectives The main objective is to analyze long-term survival (15 years) and major cardiovascular complications (MACE, (early 30-day death, stroke, any prosthesis reoperation, and major bleeding), in patients aged 50-65 years who underwent isolated aortic valve replacement (AVR) due to severe aortic stenosis . Secondary objectives were to analyze the evolution of transprosthetic gradients by echocardiography,, and degree of significant structural degeneration in bioprostheses. Material and Method: A retrospective analytical study of patients aged 50-65 years who underwent AVR surgery for stenosis between 2000-2015 in 30 centers with a Cardiovascular Surgery Dept. in SPAIN as an inclusion criterion. As exclusion criteria, autonomic change of residence, need for concomitant surgery, previous cardiac interventions and infective endocarditis. Survival analysis and clinical data records will be performed through the Public Health Care computed medical records , and direct telephone contact with family and / or relatives, in case of doubts. A crude analysis of the data and a posterior analysis by propensity score matching with SPSS or R software will be carried out using a 1: 1 or 2:1 "nearest neighbour" matching protocol based on the Number of total bioprosthesis. A total sample of more than 5000 cases is expected, of which about 1000 would be bioprostheses that would serve as a basis for the pairing. According to previous data(ANDALVALVE STUDY), to find a 4.8% difference in the primary endpoint, two groups of 1025 patients are required for a p = 0.05 and 80% for a bilateral contrast of two independent proportions. Subanalysis will be performed by subgroups of age (50-55 vs. 55-65 years) and another according to the mark of the 2 prostheses of each type most implanted. All statistical analyzes will be two-tailed with an alpha error of 0.05 to consider statistically significant data, and will be reviewed by IBIMA or Private biostatistics. Competing risks analysis will be performed to calculate the cumulative incidence of stroke, reoperation and major bleeding for each prosthesis type. Conclusions: A positive result (similar survival in group B, with lower complications) could change the current indications of AVR in our environment, allowing the age of indication for bioprostheses in European guidelines to be reduced below 60 years
Study Type
OBSERVATIONAL
Enrollment
5,000
Surgical AVR with bioprosthetic or mechanical prosthesis
Hospital Universitario Virgen de La Victoria
Málaga, Spain
RECRUITINGNumber of participants alive
Survival since surgery
Time frame: From date of surgery until the date of death from any cause, assessed up to 18 years
Late postoperative combined endpoint of 4 Major Adverse Cardiovascular Events (MACE) complications
Early 30-day Mortality, major bleeding, stroke and need of any prosthesis reoperation
Time frame: From date of surgery until the date of first documented MACE (see description) or date of death from any cause, whichever came first, assessed up to 18 years
Cumulative incidence of stroke at 15 years between groups
stroke cumulative incidence over time (competing risk analysis)
Time frame: From date of surgery until the date of first documented stroke or date of death from any cause, whichever came first, assessed up to 18 years
Cumulative incidence of prosthesis reoperation at 15 years between groups
reoperation cumulative incidence over time (competing risk analysis)
Time frame: From date of surgery until the date of first documented reoperation or date of death from any cause, whichever came first, assessed up to 18 years
Cumulative incidence of major bleeding at 15 years between groups
major bleeding cumulative incidence over time (competing risk analysis)
Time frame: From date of surgery until the date of first documented major bleeding or date of death from any cause, whichever came first, assessed up to 18 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.